These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3127186)

  • 1. Alteplase: a tissue plasminogen activator for acute myocardial infarction.
    Zeller FP; Spinler SA
    Drug Intell Clin Pharm; 1988 Jan; 22(1):6-14. PubMed ID: 3127186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
    Rogers SD; Riemersma LB; Clements SD
    Pharmacotherapy; 1987; 7(4):111-21. PubMed ID: 3120160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Tebbe U; Tanswell P; Seifried E; Feuerer W; Scholz KH; Herrmann KS
    Am J Cardiol; 1989 Sep; 64(8):448-53. PubMed ID: 2505604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction.
    McLeod DC; Coln WG; Thayer CF; Perfetto EM; Hartzema AG
    Ann Pharmacother; 1993; 27(7-8):956-62. PubMed ID: 8364282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M
    Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks versus benefits: the alteplase experience.
    Green JA
    Am J Hosp Pharm; 1989 Nov; 46(11 Suppl 2):S15-9. PubMed ID: 2513714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
    Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
    Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
    Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
    Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
    Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.